Overview
Chengcheng Fu practices in Suzhou, China. Fu is rated as an Experienced expert by MediFind in the treatment of Hemolytic Anemia. Their top areas of expertise are Multiple Myeloma, Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Leukemia, and Bone Marrow Transplant.
Their clinical research consists of co-authoring 115 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles in the study of Hemolytic Anemia.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
3 Clinical Trials
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Bone Marrow TransplantFu isDistinguished. Learn about Bone Marrow Transplant.
- Multiple MyelomaFu isDistinguished. Learn about Multiple Myeloma.
- Advanced
- Acute Lymphoblastic Leukemia (ALL)
- Acute Myeloid Leukemia (AML)
- AnemiaFu isAdvanced. Learn about Anemia.
- Aplastic AnemiaFu isAdvanced. Learn about Aplastic Anemia.
- Graft Versus Host Disease (GvHD)
- LeukemiaFu isAdvanced. Learn about Leukemia.
- Experienced
- Acute Megakaryoblastic Leukemia
- Adult T-Cell LeukemiaFu isExperienced. Learn about Adult T-Cell Leukemia.
- AgranulocytosisFu isExperienced. Learn about Agranulocytosis.
- B-Cell LymphomaFu isExperienced. Learn about B-Cell Lymphoma.
- Blood ClotsFu isExperienced. Learn about Blood Clots.
- Chronic Graft Versus Host Disease (cGvHD)